MOS President Testifies Against Missouri HJR 117

On March 22, 2022, President of the Missouri Oncology Society (MOS) Joseph Muscato, MD, FACP, Missouri Cancer Associates, testified against HJR 117, which if signed into law, would allow the legislature to turn down funding for Medicaid Expansion yearly, putting our patients at risk—each year—of losing coverage.

Additionally, the bill would place work reporting requirements on those in the expansion population, creating bureaucratic barriers and additional access challenges for patients with cancer, potentially causing Medicare patients to lose their healthcare.

MOS believes expansion will go a long way in providing greater access to cancer screening, diagnosis, and treatment for Missourians. Last month, MOS and the Association for Clinical Oncology wrote a letter to Chairman Cody Smith and members of the House Budget Committee expressing concern with HJR 117 and the seriously negative consequences it could have on patients with cancer.

MOS strongly opposes HJR 117 and believes that no individual diagnosed with cancer should be without health insurance that guarantees access to high-quality cancer care.

MOS Issues Protest Letter to Payers on IV Iron Therapy Policy

July 13, 2022

The Missouri Oncology Society (MOS) issued a letter protesting payer policies that direct providers to use only one type of intravenous iron therapy.

The policy’s economic considerations seem to focus on product acquisition costs only and fail to take into account the multitude of issues that increase costs to the patient and provider.

Read the Letter